Arran Chemical Company, based in Athlone, Ireland, has completed stage II of its three stage ADAPT (Arran Deploys Advanced Production Technologies) Euro investment strategy. The investment increases capacity, further application of its selectAZyme biocatalysis technology and implementation of flow chemistry.
 
Following acquisition by the Almac Group in November 2015, Arran has completed a program of investment in people and infrastructure. In 2017, Arran’s manufacturing plant assets have been upgraded bringing total manufacturing capacity to approximately 85 m³ with vessels ranging from kilo laboratory scale to 8 m³. The final phase of investment will involve the introduction of specialist flow manufacturing technologies.
 
“With the completion of Stage II of our ADAPT strategy, we deliver on our promise to our clients to offer solutions which are economically sound, safe, scalable and high quality through the application of new capacity and enzyme technology.” said Tom Moody, vice president Technology Development and Commercialization, Arran Chemical Company. “We are determined to remain at the forefront of innovation to ensure our customers receive best-in-class solutions with uninterrupted supply. This will be further augmented with the initiation of Stage III and subsequent build of flow chemistry capabilities.”